With a focus on out-of-favor equities in the volatile high-technology, biotechnology, and natural resources sectors, we invest in companies with hidden deep value. The fund is led by a veteran researcher, whose core competency is in unraveling murky stories and strategically sifting through fundamentals. With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
Recent graduate from Bulls on Wall Street and a full time day trader. I have been an investor in the stock market for over 20 years. It wasn't until Stocktwits and Twitter came out that I realized I was missing the boat in the market.
I was your typical Buy and hold kind of guy and I had some fantastic wins. However, I also had some mammoth losses with that strategy. I read hundreds of books, went to investment seminars, subscribed to the Wall street Journal. IBD, Barron's and countless other financial publications. I spent thousands of hours studying and reading about the macro economy and companies I wanted to invest in. I studied company financials, read every article about them, listened to conference calls, looked into management, checked out their product or service all in the hopes of investing in the next Apple, Microsoft, Walmart, early and becoming an overnight millionaire.
Then I started following day traders on Twitter and Stocktwits and I watched these traders make some pretty impressive profits holding a stock for literally 10 minutes or an hour. I actually watched one individual make an obscene amount of money in one stock both on the way up and then on the way down in about 4 hours. The kicker for me was when he concluded his trading in that stock he asked " Hey does anyone know what that company does?" I was floored!! They were in and out in one day and holding a cash position overnight. Not having to worry about waking up the following morning to some negative Press release about one of the companies they are invested in, or the overall macro economy that sends markets or your stock plunging.
It was then that I decided to educate myself and learn this craft to become a full time trader. Now I am blessed and living my dream of making a living doing what I love as a day trader and blogging about my journey. You know you have passion for your job when you are sad that its Friday and you can't wait till Monday.
Ray 69 worked as a supplier of marketing goodies to the international pharma industry for his whole working life. Retired wealthy by taking candy from the dummies that populate the industry. Even now while they proclaim to know the big pharma model is bust they still haven't got the guts to make the radical jump into the new world
A well rounded investor with a knack for what's coming and what will work. I have an interest in companies with disruptive technology and a variety of other niche players. I have proprietary methods of finding undervalued, and under-appreciated stocks with huge potential.
Farah Merchant, Capital Markets Advisor, Proactive Capital Group
ProActive Capital Group, LLC (“PCG”) is dedicated to the discovery and creation of shareholder value for public companies. PCG has specific experience with life science, high technology and international companies.
PCG provides its clients with capital market advisory, strategic communication and multimedia marketing services. We adapt these services to each client’s particular needs to successfully reach and influence key capital market participants in order to maximize shareholder value.
PCG’s capital market advisory services include overall investor strategy development to increase and leverage investor awareness, visibility & credibility.
PCG’s strategic communications services leverage digital media channels to further increase awareness to all key constituents.
PCG’s multimedia marketing services include direct mail, email marketing, investor presentation production, video production and website development
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.